Browsing by Author "Hood, Korey"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Assessing the efficacy, safety and utility of 6-month day-and-night automated closed-loop insulin delivery under free-living conditions compared with insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, multicentre, multinational, single-period, randomised, parallel group study protocol
    (BMJ, 2019-06-03) Musolino, Gianluca; Allen, Janet M.; Hartnell, Sara; Wilinska, Malgorzata E.; Tauschmann, Martin; Boughton, Charlotte; Campbell, Fiona; Denvir, Louise; Trevelyan, Nicola; Wadwa, Paul; DiMeglio, Linda; Buckingham, Bruce A.; Weinzimer, Stuart; Acerini, Carlo L.; Hood, Korey; Fox, Steven; Kollman, Craig; Sibayan, Judy; Borgman, Sarah; Cheng, Peiyao; Hovorka, Roman; Pediatrics, School of Medicine
    INTRODUCTION: Closed-loop systems titrate insulin based on sensor glucose levels, providing novel means to reduce the risk of hypoglycaemia while improving glycaemic control. We will assess effectiveness of 6-month day-and-night closed-loop insulin delivery compared with usual care (conventional or sensor-augmented pump therapy) in children and adolescents with type 1 diabetes. METHODS AND ANALYSIS: The trial adopts an open-label, multicentre, multinational (UK and USA), randomised, single-period, parallel design. Participants (n=130) are children and adolescents (aged ≥6 and <19 years) with type 1 diabetes for at least 1 year, and insulin pump use for at least 3 months with suboptimal glycaemic control (glycated haemoglobin ≥58 mmol/mol (7.5%) and ≤86 mmol/mol (10%)). After a 2-3 week run-in period, participants will be randomised to 6-month use of hybrid closed-loop insulin delivery, or to usual care. Analyses will be conducted on an intention-to-treat basis. The primary outcome is glycated haemoglobin at 6 months. Other key endpoints include time in the target glucose range (3.9-10 mmol/L, 70-180 mg/dL), mean sensor glucose and time spent above and below target. Secondary outcomes include SD and coefficient of variation of sensor glucose levels, time with sensor glucose levels <3.5 mmol/L (63 mg/dL) and <3.0 mmol/L (54 mg/dL), area under the curve of glucose <3.5 mmol/L (63 mg/dL), time with glucose levels >16.7 mmol/L (300 mg/dL), area under the curve of glucose >10.0 mmol/L (180 mg/dL), total, basal and bolus insulin dose, body mass index z-score and blood pressure. Cognitive, emotional and behavioural characteristics of participants and caregivers and their responses to the closed-loop and clinical trial will be assessed. An incremental cost-effectiveness ratio for closed-loop will be estimated. ETHICS AND DISSEMINATION: Cambridge South Research Ethics Committee and Jaeb Center for Health Research Institutional Review Office approved the study. The findings will be disseminated by peer-review publications and conference presentations.
  • Thumbnail Image
    Item
    ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring
    (Wiley, 2022) Tauschmann, Martin; Forlenza, Gregory; Hood, Korey; Cardona-Hernandez, Roque; Giani, Elisa; Hendrieckx, Christel; DeSalvo, Daniel J.; Laffel, Lori M.; Saboo, Banshi; Wheeler, Benjamin J.; Laptev, Dmitry N.; Yarhere, Iroro; DiMeglio, Linda A.; Pediatrics, School of Medicine
  • Thumbnail Image
    Item
    Response to Comment on Young-Hyman et al. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126-2140
    (American Diabetes Association, 2018-03) Young-Hyman, Deborah; de Groot, Mary; Hill-Briggs, Felicia; Gonzalez, Jeffrey S.; Hood, Korey; Peyrot, Mark; Department of Medicine, Indiana University School of Medicine
  • Thumbnail Image
    Item
    Response to Comments on Young-Hyman et al. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126-2140
    (American Diabetes Association, 2017-09) Young-Hyman, Deborah; de Groot, Mary; Hill-Briggs, Felicia; Gonzalez, Jeffrey; Hood, Korey; Peyrot, Mark; Medicine, School of Medicine